The IDN Consolidation Nobody Is Pricing Into Their 2027 Forecast

The forecast that assumes stability

Open a HealthTech company's 2027 revenue forecast and look at the customer count assumptions. In almost every case, the forecast assumes that today's customer list will still exist as distinct buying entities. It will not.

Health-system consolidation has been running for a decade and it is accelerating. IDNs are acquiring community hospitals. Regional systems are merging with other regional systems. Private-equity-backed platforms are rolling up specialty practices. The buying entity you sold to in 2024 may be a wholly owned subsidiary of a different buying entity by 2027, and that different entity may already have a competing vendor under contract.

What consolidation actually does to your book

Consolidation is bad for the acquired vendor in almost every scenario. If the acquiring IDN already uses a competitor, your contract does not survive the next renewal. If the acquiring IDN uses nobody, your contract survives but at renegotiated pricing that favors the larger buyer. If the acquiring IDN uses your product but at a different tier or configuration, you spend the next twelve months in an integration and standardization conversation that consumes resources you did not budget.

The only good outcome is being the incumbent when a smaller system gets acquired and standardizing across the combined footprint. That outcome exists. It is rarer than founders assume, because the acquiring party usually gets to choose the standard.

The math founders are not running

A founder with fifty health-system customers should be running a scenario where ten to fifteen of them are involved in a material M&A event within the next thirty-six months. This is not a worst case. It is a base case given current consolidation rates.

Of those ten to fifteen, roughly a third will result in contract termination or non-renewal. Roughly a third will result in renegotiation at worse terms. Roughly a third will be neutral or positive. This produces a specific range of gross retention degradation that is entirely predictable and almost never modeled.

The founders who model this end up making very different strategic decisions than founders who do not. They over-index on winning at the largest IDNs even if the deals take longer and the pricing is worse, because those are the accounts that end up as the acquirer rather than the acquired. They build multi-year contracts with change-of-control clauses that protect the vendor economics. They price for consolidation risk in the initial deal rather than getting caught by it later.

Why nobody talks about it

Nobody talks about it because it is bad news for the story every HealthTech company wants to tell investors. The story is that healthcare is a large fragmented market with a long tail of buyers. The consolidation reality is that the buying entities are getting fewer, larger, more sophisticated, and better able to extract vendor concessions. Those two stories are in direct tension. The consolidation story is truer. The fragmentation story is more fundable.

The uncomfortable question

The uncomfortable question for any HealthTech founder is this: if half your customers get acquired in the next three years, what does your revenue base look like, and what does your board conversation look like when it does. If you cannot answer that question with specifics, your 2027 forecast is not a forecast. It is a wish.